T&L Co., LTD.
340570KOSDAQPharmaceuticals
T&L Co., LTD. (340570, KOSDAQ) reported KRW 164bn revenue in 2025.
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2023 | 115 | 31 | 27 | 142 | 130 | Consolidated |
| 2024 | 175 | 57 | 46 | 197 | 171 | Consolidated |
| 2025 | 164 | 46 | 38 | 217 | 201 | Consolidated |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2023 | 26.7% | 23.8% | 91.2% | 21.2% |
| 2024 | 32.6% | 26.5% | 87% | 27.1% |
| 2025 | 28.2% | 23.2% | 92.7% | 18.9% |
Revenue moved 42.2% between 2023 and 2025.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
Market size
| Market capitalisation | KRW 452bn |
|---|---|
| Close price | KRW 28,100 |
| Listed shares | 16,070,120 |
| Price as of | 20260909 |
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
Workforce — a side measure, not the main one
| Employees (2025) | 237 |
|---|---|
| Women | 77 (32.5%) |
| Average tenure | 4.9 years |
| Annual pay, men | KRW 81,737,500 |
| Annual pay, women | KRW 66,974,026 |
| Pay ratio, women to men | 81.9% |
Other companies in Pharmaceuticals
181 listed companies file under this classification. Showing 12.